Amarin Faces Suit by End Payors Alleging Vascepa Supply Lock-Up

Amarin and four suppliers of the active ingredient in the heart drug Vascepa, its only product, were sued by benefits providers in a proposed class action alleging they engaged in anticompetitive conduct aimed at limiting one generic-drug maker’s launch of a cheaper version and preventing another’s launch altogether.

• Two providers of benefits for fire officers and families seek cash compensation for overcharges, including disgorgement of “unjust enrichment” and restitution via constructive trust, and order blocking them from continuing cited conduct, according to complaint filed Wednesday in federal court in Trenton, New Jersey
• Icosapent ethyl, Vascepa’s active ingredient, derived from fish ...